

## HISTOPATHOLOGY REPORTING GUIDE:

### Malignant ovarian surface epithelial/stromal tumours

Last name.....Date of birth.....  
Forename .....  
Patient identifiers.....Date of request .....

**Clinical History**.....  
Clinical presentation .....  
Hormonal status.....Medical history .....Hormonal therapy .....  
Family history.....  
Previous biopsies or cytological samples .....  
Tumour markers .....  
Previous chemotherapy .....

#### Details of surgical specimen

Left  Right   
Biopsy  partial oophorectomy  oophorectomy  salpingo-oophorectomy   
Hysterectomy with salpingo-oophorectomy  pelvic exenteration   
**Accompanying specimens**  
peritoneal biopsy  omentum  appendix  peritoneal washings/ascitic fluid   
lymph nodes (specify) .....other (specify)

#### Gross description

##### Tumour

Intact tumour  fragmented tumour  ovarian capsule: intact  breached   
Macroscopic surface involvement: yes  no   
Tumour size in 3 dimensions ....x....x....mm.  
Tumour colour .....tumour consistency.....  
Presence of cysts  presence of papillary areas  presence of solid areas   
Tumour necrosis  tumour haemorrhage

##### Accompanying specimens

Biopsies (dimensions) .....mm  
Omentum (dimensions) .....mm (description).....  
Appendix (dimensions) .....mm (description).....  
Lymph nodes (dimensions) .....mm  
Others specimens.....

**Relationship to adjacent or attached structures**.....  
.....

**RECOMMENDATIONS FOR THE REPORTING OF OVARIAN SURFACE EPITHELIAL/STROMAL TUMOURS**  
**European Society of Pathology: Gynaecopathology Working Group**

**Data to be included in the final pathology report - I**

Histological type (World Health Organization (WHO) 2002 classification (15))

- Serous tumours 
  - Malignant 
    - Adenocarcinoma
    - Surface papillary adenocarcinoma
    - Adenocarcinofibroma
  - Borderline tumours 
    - Papillary cystic tumour
    - Surface papillary tumour
    - Adenofibroma, cystadenofibroma
  - Benign 
    - Cystadenoma
    - Papillary cystadenoma
    - Surface papilloma
    - Adenofibroma and cystadenofibroma
- Mucinous tumours 
  - Malignant 
    - Adenocarcinoma
    - Adenocarcinofibroma
  - Borderline tumours 
    - Intestinal type
    - Endocervical-like
  - Benign 
    - Cystadenoma
    - Adenofibroma and cystadenofibroma
- Endometrioid tumours 
  - Malignant 
    - Adenocarcinoma
    - Adenocarcinofibroma
    - Malignant Mullerian mixed tumour
    - Adenosarcoma
    - Endometrioid stromal sarcoma (low grade)
    - Undifferentiated ovarian sarcoma
  - Borderline tumours 
    - Cystic tumour
    - Adenofibroma and cystadenofibroma
  - Benign 
    - Cystadenoma
    - Adenofibroma and cystadenofibroma
- Clear cell tumours 
  - Malignant 
    - Adenocarcinoma
    - Adenocarcinofibroma
  - Borderline tumours 
    - Cystic tumour
    - Adenofibroma, cystadenofibroma
  - Benign 
    - Cystadenoma
    - Adenofibroma and cystadenofibroma
- Transitional cells tumours 
  - Malignant 
    - Transitional cell carcinoma (non-Brenner type)
    - Malignant Brenner tumour
  - Borderline tumours 
    - Borderline Brenner tumour
  - Benign 
    - Brenner tumour
- Squamous cell tumours 
  - Squamous cell carcinoma
  - Epidermoid cyst
- Mixed epithelial tumours (specify components) 
  - Malignant
  - Borderline
  - Benign
- Undifferentiated and unclassified tumours 
  - Undifferentiated carcinoma
  - Adenocarcinoma, not otherwise specified

**Data to be included in the final pathology report - II**

Histological grade:

Serous carcinoma:           Low-grade            High-grade

Carcinosarcoma, clear cell carcinoma, undifferentiated carcinoma:   High-grade/grade3

Endometrial and mucinous adenocarcinoma: grade 1            grade 2            grade 3

**Histological findings to be included in the final pathology report - III**

Laterality:   right            left

Microscopic evidence of lymphovascular invasion:   Yes            No            Not assessable

Involvement of ovarian capsule:                        Yes            No            Not assessable

Malignant cells in peritoneal/ascitic fluid:            Yes            No            Not assessable

Peritoneal deposits:                                        Present            Absent            Not assessable

Tubal involvement:                                        No            Macroscopic            Microscopic

Uterine serosal involvement:                            No            Macroscopic            Microscopic

Omental involvement: No            Macroscopic            Microscopic            <20mm            >20mm

Peritoneal metastasis: No            Yes            <20mm            >20mm

Lymph node involvement:                                No            Yes

Other findings (specify):.....

Distant metastasis:                                        Present            Absent            Not known

**Data to be included in the final pathology report - IV**

Pre-existing borderline tumour:   Present            Absent

Endometriosis:                        Present            Absent

Post chemotherapy changes:        Present            Absent

Immunohistochemistry (optional; specify):

.....

Other ancillary studies (optional; specify):.....

**RECOMMENDATIONS FOR THE REPORTING OF OVARIAN SURFACE EPITHELIAL/STROMAL TUMOURS**  
**European Society of Pathology: Gynaecopathology Working Group**

**Data to be included in the final pathology report -**

**Pathologic ovarian staging form:** extent of disease through completion of definitive surgery (22)

<b>Primary tumour (T)</b>	<b>TNM category</b>	<b>FIGO STAGE</b>	
Primary tumour cannot be assessed:	<b>TX</b>		<input type="checkbox"/>
No evidence of primary tumour:	<b>T0</b>		<input type="checkbox"/>
Tumour limited to ovaries (one or both):	<b>T1</b>	<b>I</b>	<input type="checkbox"/>
Tumour is limited to one ovary, capsule intact, no tumour on ovarian surface, no cancer cells in the abdominal fluid:	<b>T1a</b>	<b>IA</b>	<input type="checkbox"/>
Tumours limited to both ovaries, capsules intact, no cancer cells in the abdominal fluid:	<b>T1b</b>	<b>IB</b>	<input type="checkbox"/>
Tumour limited to one or both ovaries with any of the following: capsule ruptured, tumour on ovarian surface, cancer cells in the abdominal fluid:	<b>T1c</b>	<b>IC</b>	<input type="checkbox"/>
The tumour involves one or both ovaries with pelvic extension	<b>T2</b>	<b>II</b>	<input type="checkbox"/>
Extension and/or implants on uterus and/or tubes. No cancer cells are found in the abdominal fluid:	<b>T2a</b>	<b>IIA</b>	<input type="checkbox"/>
Extension and/or implants on other pelvic tissue. No cancer cells in the abdominal fluid:	<b>T2b</b>	<b>IIB</b>	<input type="checkbox"/>
Pelvic extension and/or implants with cancer cells in the abdominal fluid:	<b>T2c</b>	<b>IIC</b>	<input type="checkbox"/>
Tumour involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis	<b>T3</b>	<b>III</b>	<input type="checkbox"/>
Microscopic peritoneal metastasis beyond the pelvis, no macroscopic tumour	<b>T3a</b>	<b>IIIA</b>	<input type="checkbox"/>
Macroscopic peritoneal metastasis beyond pelvis 2 cm or less:	<b>T3b</b>	<b>IIIB</b>	<input type="checkbox"/>
Peritoneal metastasis beyond pelvis more than 2 cm and/or regional lymph nodes metastasis:	<b>T3c</b>	<b>IIIC</b>	<input type="checkbox"/>

Note: Liver capsule metastasis T3/Stage III.  Liver parenchymal metastasis M1/Stage IV  Pleural effusion must have positive cytology for M1/Stage IV

<b>Regional lymph nodes (T)</b>	<b>TNM category</b>	<b>FIGO STAGE</b>	
Regional lymph nodes cannot be assessed:	<b>NX</b>		<input type="checkbox"/>
No regional lymph nodes metastasis:	<b>N0</b>		<input type="checkbox"/>
Regional lymph nodes metastasis:	<b>N1</b>	<b>IIIC</b>	<input type="checkbox"/>

  

<b>Distant metastasis (M)</b>	<b>TNM category</b>	<b>FIGO STAGE</b>	
N0 (No pathological M0; use the clinical M to complete stage group)	<b>M0</b>		<input type="checkbox"/>
Distant metastasis (excludes peritoneal metastasis)	<b>M1</b>	<b>IV</b>	<input type="checkbox"/>